bioAffinity Technologies Inc Warrant 2022- on bioAffinity
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−20.8714 USD
−9.04 M USD
9.36 M USD
4.35 M
About bioAffinity Technologies, Inc.
Sector
Industry
CEO
Maria Zannes
Website
Headquarters
San Antonio
Founded
2014
Identifiers
3
ISIN US09076W1172
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
Displays a symbol's price movements over previous years to identify recurring trends.